Abstract: Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunostimulatory compositions disclosed herein can be directed to preventing or treating an infection, cancer or other immunocompromising health condition in the subject. In some embodiments, the immunostimulatory compositions disclosed herein enhance non-specific immune responses systemically or locally in the subject to treat or reduce the risk of onset of a health condition. In some embodiments, immunostimulatory compositions disclosed can be used to induce a non-specific immune response within mucosal surfaces such as the nasopharynx, upper respiratory tract, eye, GI tract, and reproductive tract to induce a non-specific immune response in order to reduce onset of or treat an infection or other health condition.

Abstract: Embodiments of the present invention relate to compositions and methods for activating canine OX40 to treat a condition in dogs. In certain embodiments, the condition can be cancer or an immunosuppressed condition in dogs and OX40 activation treats, ameliorates or prevents onset or progression of the condition. In other embodiments, compositions disclosed herein generally relate to compositions including, but not limited to, activating antibodies having specific affinity for OX40 for inducing activity of canine OX40. In other embodiments, compositions disclosed herein can be used for treating certain cancers or an immunosuppressed condition to treat the cancer or alleviate immunosuppression in dogs. In certain embodiments, other immune activators can be administered in combination with OX40 activating antibodies such as Toll-Like Receptor (TLR) ligands alone or in combination with other non-specific immunostimulant agents.

Abstract: The present invention provides cancer stem cell vaccines useful for treating or preventing a variety of tumors, as well as related methods of producing cancer stem cells and antigens thereof and producing vaccine adjuvants with enhanced activity for use with the stem cell vaccines.

Abstract: Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds or infections of the eye. In some embodiments, immunogenic ocular formulations disclosed herein include combinations of agents for prolonged exposure to the eye for improved outcomes.

Abstract: Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds of the eye.

Abstract: The present disclosure relates to methods for diagnosing and treating inflammatory bowel disease (IBD) in companion animals.

Abstract: Provided herein are compositions containing an infusion ready population of activated, allogeneic mesenchymal stem cells and one or more pharmaceutically acceptable carriers, diluents, or excipients. Also provided are methods of treating infected wounds in mammals by administering an effective amount of activated mesenchymal stem cells to the mammal.

Abstract: Provided herein are compositions containing an infusion ready population of activated, allogeneic mesenchymal stem cells and one or more pharmaceutically acceptable carriers, diluents, or excipients. Also provided are methods of treating infected wounds in mammals by administering an effective amount of activated mesenchymal stem cells to the mammal.

Abstract: Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds of the eye.

Abstract: The disclosed compositions and methods relate to an immunogenic composition that, in certain aspects, comprise cationic liposomes; a mixture of toll like receptor 3 (TLR3) and toll like receptor 9 (TLR9) ligands; and a cellular adhesion agent, and methods of using such compositions. In certain aspects, disclosed compositions are administered to a mammal to induce a non-specific innate immune response at mucosal surfaces. In further aspects, disclosed compositions are administered to a mammal in conjunction with an antigen to enhance the immune response of the mammal to the antigen.

Abstract: Provided herein are compositions containing an infusion ready population of activated, allogeneic mesenchymal stem cells and one or more pharmaceutically acceptable carriers, diluents, or excipients. Also provided are methods of treating infected wounds in mammals by administering an effective amount of activated mesenchymal stem cells to the mammal.

Abstract: The present invention provides cancer stem cell vaccines useful for treating or preventing a variety of tumors, as well as related methods of producing cancer stem cells and antigens thereof and producing vaccine adjuvants with enhanced activity for use with the stem cell vaccines.

Abstract: The disclosed compositions and methods relate to an immunogenic composition that, in certain aspects, comprise cationic liposomes; a mixture of toll like receptor 3 (TLR3) and toll like receptor 9 (TLR9) ligands; and a cellular adhesion agent, and methods of using such compositions. In certain aspects, disclosed compositions are administered to a mammal to induce a non-specific innate immune response at mucosal surfaces. In further aspects, disclosed compositions are administered to a mammal in conjunction with an antigen to enhance the immune response of the mammal to the antigen.